Who owns DOC GENERICI?

DOC GENERICI has been 100% owned by CVC since March 2016.

At what enterprise value was DOC GENERICI acquired in 2016?

During the acquisition of DOC GENERICI by CVC in 2016, the transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR.

What was the EV/EBITDA of DOC GENERICI when it was acquired by CVC?

The estimated EV/EBITDA multiple for DOC GENERICI is in the range of 10x - 18x.

When was DOC GENERICI acquired by CVC?

DOC GENERICI was acquired by CVC in 2016.

What was the revenue of DOC GENERICI at the time of the deal?

The revenue of DOC GENERICI at the time of the deal is estimated to be in the range of 100M - 200M EUR.

What was the EBITDA of DOC GENERICI during the acquisition?

DOC GENERICI's EBITDA is estimated to be in the range of 50M - 100M EUR.

How is the data for the DOC GENERICI acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the DOC GENERICI deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://bebeez.it/private-equity/cvc-compra-doc-generici-da-charterhouse-che-porta-casa-un-guadagno-super/

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaDOC GENERICI

03/2016

DOC GENERICI acquired by CVC

ITALY Life Sciences / Pharma & Biotech / Generics / Labs EV 500M - 1.5b EUR

Context

CVC Capital Partners acquired 100% of DOC Generici from Charterhouse Capital Partners, outbidding other major PE firms like Blackstone in a competitive auction. The transaction was supported by a debt package provided by UniCredit and HSBC. The deal represented a highly successful exit for Charterhouse, which reportedly achieved an Internal Rate of Return (IRR) of 40% and a 2.7x money multiple on its 2013 investment. CVC's strategy for the investment was to leverage DOC's dominant market share and asset-light structure to drive organic growth as generic penetration in Italy continued to increase towards European averages.

It is worth noting that the fund Charterhouse took control of Doc Generici through an LBO in 2013.

DOC GENERICI, which reported an EBITDA margin of in 2015, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

DOC Generici is Italy's leading independent generic pharmaceutical company. It operates an asset-light model, focusing on the marketing and distribution of a vast portfolio of out-of-patent drugs across multiple therapeutic areas (cardiovascular, gastrointestinal, metabolic). It holds one of the largest market shares in the Italian retail pharmacy channel.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2015

2014

Other operations with DOC GENERICI

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
07/2022	TPG	DOC GENERICI	ITALY	Generics / Labs
04/2019	ICG / MERIEUX EQUITY PARTNERS	DOC GENERICI	ITALY	Generics / Labs
07/2013	CHARTERHOUSE	DOC GENERICI	ITALY	Generics / Labs

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 100M - 200M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DOC GENERICI by CVC are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: cvc